entinostat + anastrozole
Phase 2TerminatedDevelopment Stage
Estrogen Receptor-negative Breast Cancer
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
Oct 1, 2010 → May 1, 2017
About entinostat + anastrozole
entinostat + anastrozole is a phase 2 stage product being developed by Syndax Pharmaceuticals for Estrogen Receptor-negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01234532. Target conditions include Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Estrogen Receptor-negative Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01234532 | Phase 2 | Terminated |
Competing Products
20 competing products in Estrogen Receptor-negative Breast Cancer